India’s clinical trials ecosystem is entering a rapid growth phase, supported by regulatory reform, expanding infrastructure, and rising global interest.
India’s Rising Position in Global Clinical Research
India’s clinical trials and research ecosystem is entering a new phase of growth, supported by regulatory reform, rising global interest, and stronger domestic research capabilities. As of 2026, the country is being positioned not just as a cost-effective trial location, but as an increasingly important center for innovation, patient recruitment, and early-stage development.
In recent years, India has seen a sharp increase in registered clinical trials, reflecting greater activity across pharmaceuticals, biologics, and medical research programs. This expansion is being driven by a large and diverse patient base, improving infrastructure, and a more supportive policy environment for sponsors, CROs, and research institutions.
Approximately 18,000 new clinical trials were registered in India in 2024 alone, representing a 50% increase from the previous year. The Clinical Trials Registry of India (CTRI) now holds over 94,730 trials registered since 2000, positioning India as a strategic partner for global pharmaceutical companies.
Regulatory Reforms Accelerating Drug Approvals
One of the most important recent developments is the amendment to India’s New Drugs and Clinical Trials framework in 2026. The updated rules aim to simplify approvals, reduce timelines, and introduce a prior-intimation route for certain low-risk categories, while retaining tighter controls for high-risk products such as cytotoxic drugs, narcotics, and selected biologics.
These changes are expected to improve ease of doing business for companies involved in drug development and bioequivalence work. The reduction in some approval timelines from 90 working days to 45 working days could help accelerate pre-clinical and clinical planning, especially for manufacturers and research sponsors seeking faster execution.
The amendment introduces a “Prior Intimation” system where manufacturers can proceed based on online acknowledgment for analytical and non-clinical testing, except for high-risk categories like sex hormones, beta-lactams, and live biologics. Drugs manufactured under these provisions remain strictly for research and cannot be sold commercially.
Government Support Expanding Trial Infrastructure
Government support is also becoming more visible in the broader clinical research landscape. In Budget 2026, the Finance Minister announced plans to establish over 1,000 accredited clinical trial sites across India, expanding beyond major cities like Mumbai, Delhi, and Bengaluru to tier-2 and tier-3 cities.
Recent announcements have highlighted efforts to expand accredited trial sites, strengthen ethics review systems, and improve coordination across multicentric studies, all of which are essential for scaling research quality nationwide. The Indian Council of Medical Research (ICMR) has also organized its first Annual Clinical Trial Meet in 2026, focusing on innovation, ethics, and scientific excellence.
The INTENT network (Indian Clinical Trial and Education Network) by ICMR now includes 75 sites for Phase II and Phase III trials and 4 institutions for Phase I across public and private medical colleges, hospitals, and research institutes. The National Biopharma Mission has established a Clinical Trial Network supporting 5 consortia of 35 hospitals for testing biologicals in oncology, diabetology, and other therapeutic areas.
India’s Strengths in Patient Diversity and Disease Burden
India’s strengths in clinical research remain closely tied to its population diversity and disease burden. This makes the country especially valuable for trials in oncology, diabetes, cardiovascular disease, inflammation, and other therapeutic areas where diverse patient recruitment and real-world relevance are important.
India offers one of the most heterogeneous patient populations globally, with diversity in genetic makeup, disease burden, and socioeconomic status, making it especially suitable for multi-ethnic, multi-centric trials. Approximately 79% of clinical trials registered in India cater to non-communicable diseases including malignant neoplasms (11.4%), diabetes (6.7%), and cardiovascular diseases (8.1%).
The oncology segment dominated the market with the largest revenue share in 2024 and is projected to witness the fastest CAGR through 2030. Cancer is projected to affect approximately 2 million people in India by 2040 according to ICMR, emphasizing the urgent need for innovative therapies.
Market Growth and Investment Trends
The market itself is also growing steadily. Industry estimates place the India clinical trials market at roughly USD 1.5 to 1.7 billion in 2025, with continued expansion projected over the next several years as more global and domestic companies invest in research operations.
The India clinical trials market is projected to reach USD 2.22 billion by 2030, growing at a CAGR of 8.0%. The market is driven by India’s diverse population offering a unique genetic pool, cost-effectiveness (nearly half the cost of U.S./Europe), and supportive regulatory frameworks.
Global pharmaceutical companies are expanding India operations significantly. Bristol Myers Squibb invested over US$100 Mn in India for early-stage drug development through their GCC in Hyderabad, with 23 active trials as of November 2024, expected to double by 2026. Novartis has 52 active clinical trials registered in India across 335 sites with more than 2,000 patients.
Early-Phase Research and Innovation Capacity
Another clear trend is the push toward early-phase research and stronger innovation capacity. India has historically been stronger in later-stage and generic-linked work, but recent efforts are increasingly focused on Phase I capability, first-in-human studies, and translational research that can move scientific discovery closer to commercial development.
Phase I clinical trials surged 60% post-2019 reform, with India registering and conducting 1,641 Phase I trials between 2019-2024, accounting for 60% of all first-in-human trials in the country. Phase I trials are projected to witness the fastest CAGR of 9.7% through 2030.
India has made significant advancements including developing indigenous CAR-T cell therapy and engaging in numerous global, local, academic, and government-sponsored trials over 25 years. POLB 001 (a preventative for Cytokine Release Syndrome in CAR-T therapy) data is expected by mid-2026.
Digital Transformation and Decentralized Trials
Digital transformation is also reshaping how trials are designed and managed. Industry discussions in 2026 have focused on patient-centric models, decentralized and hybrid trial formats, digital tools for monitoring, and new approaches that can improve recruitment, retention, and data handling.
Artificial Intelligence has moved from a trend to a core operational tool in 2026, with AI-assisted clinical trial designs reducing trial durations by roughly 10% and significantly lowering operational costs. Companies are scaling “Smart Factories” where ISO-5 compliant robots handle sterile filling and packaging, cutting validation times in half.
This is particularly relevant in a country as geographically large and diverse as India. Hybrid and decentralized models can help extend research access beyond major metro centers, allowing more patients and healthcare institutions to participate in formal clinical research frameworks. A recent study underscores the transformative potential of decentralized clinical trials in India, revealing a growing preference for hybrid models.
Challenges and Quality Standards
At the same time, the industry continues to face practical challenges. Site readiness, investigator training, operational consistency, and regulatory compliance still vary across the ecosystem, and long-term growth will depend on improving quality and trust alongside speed.
Approval timelines of 1-2 years remain a barrier, along with ethical and regulatory hurdles and balancing local rules with international regulatory standards. While India has moved forward in nurturing innovation pipelines, there’s still a long road ahead to integrate early-stage research and late-stage product development for competitiveness in high-value drug categories.
Revised Schedule M Good Manufacturing Practices (GMP) rolled out on January 1, 2026, represents a critical regulatory change for manufacturers. Thousands of MSMEs struggle to meet these stricter international quality standards, with industry bodies like IDMA requesting a one-year extension until December 2026 to prevent plant closures.
Ethics, Oversight, and Industry Events
Ethics and oversight remain central to that process. Recent institutional discussions have emphasized stronger governance, single ethics review models for multicentre research, and the need to align research growth with scientific rigor and participant protection.
Events held in 2026 also show how clinical research is receiving greater national attention. The Indian Society for Clinical Research’s 19th Annual Conference (February 16, 2026) focused on digital innovation shaping patient-centric clinical research in India, featuring 285 speakers exploring the role of digital innovation.
International Clinical Trials Day 2026 was celebrated on May 20, 2026, hosted by the Indian Society for Clinical Research & KG Hospital. The 17th Annual Clinical Trials Summit 2026 serves as India’s premier platform to explore rapid market expansion and cutting-edge research innovations.
Strategic Importance for the Pharmaceutical Industry
For the pharmaceutical industry, this matters far beyond compliance. A stronger clinical trials environment supports faster development cycles, more credible data generation, better collaboration with global partners, and a greater role for India in the international life sciences value chain.
The patient recruitment segment is projected to grow at the fastest CAGR, fueled by India’s large and diverse population providing a rich candidate pool. Advancements in digital health technologies have improved patient registration processes, while virtual clinical trials now enable recruitment across remote areas.
Clinical research costs in India are nearly half those incurred in the U.S. and Europe, making it appealing for global pharmaceutical companies optimizing research budgets. This cost advantage, combined with a growing pool of skilled medical professionals including scientists, doctors, and researchers, ensures high-quality execution of clinical trials.
Looking Ahead: India as a Strategic Research Partner
Looking ahead, India appears well placed to deepen its role in global clinical research, provided investment in infrastructure, talent, and quality systems continues. The direction in 2026 is clear: India is moving from being seen mainly as a low-cost destination to being recognized as a more strategic and increasingly capable research partner.
With a focused strategy and targeted investments, India can establish itself as the healthcare custodian of the world by 2047. The clinical trials ecosystem is central to this vision, with emphasis on quality, completeness, and speed establishing global trust in data generated from India.
India is on a path to become a global pharma powerhouse by 2047, targeting a $450 billion industry powered by digital transformation, AI-driven innovation, and strategic collaboration. The country already ranks 3rd globally by drug volume and is known as the “Pharmacy of the World” for supplying affordable generics and vaccines to 150+ countries.